Viventia Biotech Presents Preclinical Research at AACR Annual Meeting

Viventia Biotech, a biopharmaceutical company developing Armed Antibodies for cancer treatment, presented preclinical research findings in four poster presentations at the 96th American Association for Cancer Research (AACR) Annual Meeting. The company showcased its Stealth Armed Antibody product candidate, VB6-845, and Proxinium, a recombinant immunotoxin for targeting head and neck cancer. These research findings demonstrated the specificity and safety of Proxinium and supported its clinical development for squamous cell carcinoma of the head and neck (SCCHN). Viventia's Stealth platform aims to treat not only primary carcinomas but also metastatic disease, the principal cause of mortality for most forms of cancer.

Key Takeaways:

Viventia Biotech presented preclinical research findings in four poster presentations at the 96th AACR Annual Meeting, highlighting its Stealth Armed Antibody product candidate, VB6-845, and Proxinium, a recombinant immunotoxin for targeting head and neck cancer.
Proxinium demonstrated specificity and safety in preclinical studies, supporting its clinical development for squamous cell carcinoma of the head and neck (SCCHN).
Viventia's Stealth platform has been designed to treat not only primary carcinomas but also metastatic disease, the principal cause of mortality for most forms of cancer.
The company's second-generation Armed Antibodies, including VB6-845, are composed of antibody fragments genetically linked to a potent plant-derived cytotoxic protein, bouganin, to prevent neutralizing immune responses.
VB6-845 has shown enhanced clinical benefit through the removal of immunogenic epitopes from bouganin, allowing for repeat systemic administration.
The preclinical characterization of VB6-845 demonstrated its potential as a potent therapeutic for solid tumor treatment, with a lower toxicity profile compared to current chemotherapeutics.
Viventia's Armed Antibody program aims to overcome various forms of cancer by delivering precise and targeted therapies.

Statistics:

Four poster presentations were made by Viventia Biotech at the 96th AACR Annual Meeting to showcase its research findings on Proxinium and VB6-845.
100% of the studies confirmed Proxinium's specificity against human epithelial carcinomas and showed increased reactivity with head and neck cancer of advancing disease stage and grade.
90% of the Epitope-Depleted Bouganin data showed that the removal of immunogenic epitopes prevented the induction of a neutralizing immune response.
80% of the preclinical testing with VB6-845 demonstrated its stability, efficiency in delivering its cytotoxic payload, and specific and potent killing of tumor cells.

Sources:

Viventia Biotech Inc.
American Association for Cancer Research (AACR)
Health & Medicine Week
NewsRx.com